BV is currenty FDA-aproved in combination with CHP (CHP+A) as first-line treatment for CD30 + PTCL, based E2 results (34% reduction in risk of death), an effect only demonstrable in ALCL (70% of E2 cohort) (Horwitz, Lancet, 2019). We investigated outcomes of unselected ALCL patients treated in routine practice prior to widespread approval of BV in 1L.
|Journal||British Journal of Haematology|
|Publication status||Published - 27 Apr 2020|
|Event||60th Annual Scientific Meeting of the British Society for Haematology - Birmingham, United Kingdom|
Duration: 27 Apr 2020 → 29 Apr 2020
Conference number: 60